---
title: "GLP‑1 real‑world data for obesity: A new standard for metabolic care"
description: GLP-1 therapies are changing obesity care. Claims alone miss critical insights but integrated real-world data reveals the comprehensive patient journey.
image: https://blog.healthverity.com/hubfs/glp-1-real%E2%80%90world-data-for-obesity-featured.png
---
Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/)
- [Contact](https://healthverity.com/contact/)
- [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/)
[](https://healthverity.com/)
- How We Help
- Featured Content
- [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
- [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
- Data Ecosystem
- [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/)
- [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/)
- [Precision Event Alerts](https://healthverity.com/precision-event-alerts/)
- [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/)
- [Media Measurement](https://healthverity.com/media-measurement/)
- [Insurance Underwriting](https://healthverity.com/insurance-underwriting/)
- Technology Products
- [Identity Manager (HVID)](https://healthverity.com/identity-manager/)
- [HealthVerity FLOW](https://healthverity.com/flow/portal/)
- [Governance Manager](https://healthverity.com/governance-manager/)
- [Smart Contracts](https://healthverity.com/smart-contracts-manager/)
- Symphony
- Symphony Health Platform
- [Symphony Health Overview](https://healthverity.com/symphony-health/overview/)
- [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- Symphony Solutions
- [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/)
- [HealthRankings](https://healthverity.com/symphony-health/health-rankings/)
- [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/)
- [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/)
- [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/)
- Symphony Products
- [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf)
- [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf)
- [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf)
- [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf)
- [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf)
- [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf)
- [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/)
- [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf)
- [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf)
- Symphony Technology
- [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/)
- [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf)
- [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/)
- Who We Serve
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Government](https://healthverity.com/government/)
- [Insurance](https://healthverity.com/insurance/)
- [Channel Partners](https://healthverity.com/channel-partners/)
- [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
- Resources
- [HealthVerity Blog](https://blog.healthverity.com/)
- [News & Events](https://healthverity.com/resources/news-and-events/)
- [Resource Library](https://healthverity.com/resources/resource-library/)
- [Publications](https://healthverity.com/resources/publications/)
- [The IPGE Approach](https://healthverity.com/ipge-approach/)
- [Zombie Data Explained](https://healthverity.com/get-verified/)
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)
[Request Demo](https://healthverity.com/request-demo/)
[Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/)
[](https://healthverity.com/)
- How We Help
- Symphony
- Who We Serve
- Resources
- [Careers](https://healthverity.com/careers/)
- [About Us](https://healthverity.com/about-us/)
[Request Demo](https://healthverity.com/request-demo/)
Featured Content
###### HealthVerity MarketplaceTM
The nation’s largest healthcare and consumer data ecosystem
###### taXonomy Pathways
Unique features per therapeutic area with claims, labs and EHR including notes
###### HealthVerity eXOs
AI-native real-world evidence generation
###### Identity Manager (HVID)
Standalone de-identification as a service
Data Ecosystem
HealthVerity MarketplaceTM
HealthVerity TaxonomySM
HealthVerity Notes
Precision Event Alerts
HealthVerity Mastersets
Media Measurement
Syndicated Audiences
Insurance Underwriting
Technology Products
Identity Manager (HVID)
HealthVerity for Clinical Trial Linkage
HealthVerity for Commercial
Smart Contracts
HealthVerity for Registries
Symphony Health Platform
###### Symphony Health Overview
Seamless Data. Stronger Insights. Smarter Decisions.
###### Integrated Dataverse
Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view.
###### Symphony HealthCloud
Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud.
Symphony Solutions
Health technology and business intelligence solutions
Integrated Dataverse and Source Solutions
Brand strategy and sales
HealthRankings
Market access
Patient Journey
Medicines affordability
Symphony Products
PayerSource®
PrescriberSource®
PatientSource®
PatientSourceCompleteTM
PatientSourceDUOTM
Symphony FLEXTM
CustomerSource®
DiagnosticSource®
NonRetailSource®
Symphony Technology
Symphony HealthCloud
Synoma Data Integration
Vantage Applications
Metys
###### Life Sciences
Technology solutions from development through commercialization
###### Channel Partners
HealthVerity enables partners to unlock unprecedented value and insights for clients
###### Government
Comprehensive and compliant solutions to manage the nation’s care
###### Data Ecosystem Partners
Join the nation’s largest data partner ecosystem
###### Insurance
Insurance-grade solutions that excel in managing risk and rebates
###### HealthVerity Blog
Insights and updates from industry experts
###### Publications
Peer-reviewed research and discoveries
###### News & Events
Stay informed about our latest announcements and happenings
###### The IPGE Approach
Fundamentals that power everything that we do and every solution we offer
###### Resource Library
Explore guides, webinars, and tools to enhance your understanding
###### Zombie Data Explained
Learn how data quality drives better research outcomes
[Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices), [taXonomy](https://blog.healthverity.com/tag/taxonomy)
# GLP‑1 real‑world data for obesity: A new standard for metabolic care
[By - HealthVerity,](https://blog.healthverity.com/author/healthverity) October 9, 2025
## The rise of GLP-1 therapies and the evolution of obesity treatment
Over 40% of adults in the U.S. have obesity, representing over 100 million patients.1 Not long ago, bariatric surgery was the only option for substantial weight loss among those with treatment resistant obesity. Today, a new generation of GLP-1 receptor agonists has transformed obesity and metabolic disease research and treatment. These GLP-1 drugs, including semaglutide and tirzepatide, have shown 15-25% body weight reduction in clinical trials, approaching the effectiveness of surgery. Demand for these treatments has surged and U.S. spending on GLP-1 medications **rose over 500%** from 2018 to 2023, climbing from $13.7 billion to $71.7 billion. Analysts project that within five years, annual spending on GLP-1 obesity drugs could exceed $100 billion.1
> “With the possible exception of Operation Warp Speed, GLP-1 therapies have defined the decade in terms of impact on population health. They’re ushering in a new standard of care and a renewed push towards innovation in metabolic conditions and beyond. Still, this mechanism was discovered in the 1980s - it took us 40 years to get here. As an industry, how do we speed this up? What data or evidence do we need to get these discoveries from bench to bedside faster, while prioritizing safety, efficacy, and effectiveness?”
>
> - Alexa Woodward, PhD, Senior Director of Strategic Accounts at HealthVerity
Nearly every major manufacturer is investing in obesity pipelines, including combination therapies that target multiple pathways. Tirzepatide’s success as a dual GLP-1/GIP agonist is leading the way for next-generation multi-receptor agonists, and companies are exploring oral formulations pills to win over patients averse to injections. Eli Lilly recently reported that its daily oral GLP-1 candidate (orforglipron) achieved significant weight loss (~12–15% over 36 weeks) with side effects similar to injectable GLP-1s.2 At the same time, there have been some setbacks. Pfizer halted development of its oral GLP-1 danuglipron in 2025 after a trial participant developed liver injury, reflecting safety concerns that require ongoing monitoring with real-world data.3 Mild to moderate gastrointestinal side effects are common for most patients on GLP-1s, prompting careful dose titration and monitoring.4
Beyond weight loss, researchers are also discovering benefits of GLP-1 drugs in other disease areas. A 2025 review in *Cell* highlighted the benefit of GLP-1 therapies on anti-inflammatory mechanisms involved in cardiovascular, kidney and liver conditions, and disorders like obstructive sleep apnea.5 These broad potential indications, coupled with payer concerns about affordability, access and long-term cost-effectiveness, make it clear that GLP-1 obesity treatments are more than a passing trend and they demand robust evidence and longer term real-world monitoring.
.png?width=1905&height=460&name=GLP-1%20and%20RWE%20graphic%20(1).png)
HealthVerity Podcast: GLP-1 and RWE
4:41
## Why claims data alone can’t explain real-world GLP-1 outcomes
As adoption accelerates, pharmaceutical companies are racing to innovate through new formulations, delivery options, and combination approaches that improve tolerability and long-term outcomes. Health economists and payers want to know the true eligible population and budget impact; epidemiologists and outcomes researchers need to track long-term effectiveness and safety; pharmacovigilance experts are monitoring for adverse signals beyond clinical trials. **Traditional claims data alone, however, cannot answer many of these critical questions.**
Claims can reveal when a patient fills a prescription or undergoes a procedure that was billed to their insurance, but for obesity care they rarely capture the clinical details that define treatment response. In health economics and outcomes research (HEOR) and epidemiologic studies, claims data alone leave researchers without essential information such as:
- **Body mass index (BMI) or weight trajectory** to identify obesity thresholds or track improvement
- **A1c and lipid panels** to assess cardiometabolic change
- **Liver and kidney markers** such as ALT, AST, and eGFR to evaluate comorbidities like MASH or nephropathy
- **Physician notes** that document adherence barriers, recommended dosing schedules, or dietary guidance
These gaps in claims mean that researchers are missing many aspects of the patient journey (Figure 1). Claims data might show that a patient filled a 90-day prescription of Wegovy®, then stopped. **Lab** and **electronic health record (EHR) data** can reveal why. Perhaps the patient’s liver enzymes spiked, or they experienced severe nausea or their insurer refused to cover further refills.
[](https://healthverity.com/pathways/)
**Figure 1:** A metabolic use-case comprehensive patient journey view with [taXonomy Pathways](https://healthverity.com/pathways/)
In clinical trials, GLP-1 drugs showed high adherence (over 85% of patients stayed on therapy), yet real-world use tells a different story: one large study found only 32% of obese patients remained on a GLP-1 therapy after one year, with just 27% meeting standard adherence thresholds.6 Understanding these adherence gaps and real outcomes is impossible without linking claims to the clinical evidence found in labs and EHR, including physicians notes. The problem is a data disconnect because the pharmacy and medical claims tell us that GLP-1 usage is soaring, but they don’t tell us which patients benefit, which patients fail, and why.
A recent AMA/CDC report covered the challenges with long term adherence and the introduction of new indications will drive the need for ongoing research incorporating richer data sources beyond claims.7
## The research opportunity connecting claims with real-world data
The opportunity for manufacturers, researchers, and healthcare stakeholders is to bridge this data gap and gain a comprehensive view of the GLP-1 obesity treatment journey. By integrating claims with clinical data, researchers can find insights that were previously hidden. This is particularly valuable for teams in health economics and outcomes research (HEOR), epidemiology, and pharmacovigilance who are tasked with evaluating real-world performance.
### With the right data:
- HEOR analysts can model the true impact of GLP-1 therapies – for example, linking the 15%-20% weight loss achieved by patients to downstream reductions in comorbidity and healthcare utilization.8
- Epidemiologists can better estimate the size of the eligible population (using BMI and lab criteria instead of diagnosis codes) and understand how treatment patterns evolve over years.
- Pharmacovigilance teams can proactively detect adverse events or off-label use trends by observing lab anomalies (like liver enzyme elevations) or reading physician notes that mention events like pancreatitis or gallbladder issues which might not trigger an insurance claim code.
- Market access and medical affairs teams to demonstrate the full value of these therapies. Real-world evidence can show payers which subpopulations benefit most and inform more equitable coverage policies.
The end result is a chance to maximize the health benefits of GLP-1 obesity treatments (which have enormous potential) while containing risks and costs through data-driven insights.
Figure 2: the diabetes and obesity patient journey with taXonomy Pathways.
The taXonomy Pathways solution
[**taXonomy Pathways**](https://healthverity.com/pathways/) brings closed payer claims together with lab results and EHR, including physician notes, so you can evaluate eligibility, initiation, titration, response and persistence on therapy in one research‑ready data set.
This solution is anchored by the nation’s largest source of closed medical and pharmacy claims (covering over 300 million patients across hundreds of payers with 9+ years of history), and it adds context those claims with lab data from the two largest outpatient labs that capture over **60% of U.S. lab testing,** EHR data including millions of clinical notes. The result is a **data asset** that allows your team to analyze the full obesity patient journey **in one place**, without the pain of stitching together fragmented data sources.
The dataset connects **claims, labs and EHR, including physician notes** to analyse:
- Who meets drug label or payer criteria based on actual BMI and comorbidities
- How titration and dosing progress in real-world care
- What metabolic outcomes patients achieve over time
- Which safety signals, such as liver or renal changes, emerge across populations
- Why patients discontinue or switch treatments, as documented in notes
## See real-world GLP-1 evidence in action
[Register for our webinar](https://info.healthverity.com/closing-the-evidence-gap-before-year-end) where we dive deeper into GLP-1 real-world evidence. In the meantime, if you are exploring obesity outcomes for therapies like Wegovy®, Zepbound® or next-generation weight loss drugs, we can help design a tailored real-world study. Tell us your population of interest and endpoints. With taXonomy Pathways, we will deliver a dataset and analysis framework that **you simply cannot see in claims data alone.**
Interested in getting started with taXonomy Pathways? [Download](https://blog.healthverity.com/hubfs/guide-to-comprehensive-patient-journeys.pdf) our guide to comprehensive patient outcomes.
[](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIKKyWK3512vaXoNsA5%2F9uH6ncpfVK0ysYedIkVyKjDLeOmZI5Wm6DrPNuZfwUlG3afl4GcG0%2B8bcfdlJFjDPB4phc6rlHiZrwAlsZcKOJyVxy7fzCoe%2FeSWyVsz5E3TX3WO%2BKi43wM%2BlRtQfNnhmVtWKGNBZ0JVWR2kFYxwAbVtGu%2BjgU%3D&webInteractiveContentId=196135223637&portalId=5412465)
## References
1. Institute for Clinical and Economic Review (ICER). *Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions.* Published 2023. Accessed October 2025. [https://icer.org/wp-content/uploads/2025/04/Affordable-Access-to-GLP-1-Obesity-Medications-\_-ICER-White-Paper-\_-04.09.2025.pdf](https://icer.org/wp-content/uploads/2025/04/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09.2025.pdf)
2. Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., Allen, S. E., Ahmad, N. N., & Klise, S. R. (2025). Orforglipron, an oral small-molecule glp-1 receptor agonist for obesity treatment. *New England Journal of Medicine*, NEJMoa2511774. [https://doi.org/10.1056/NEJMoa2511774](https://doi.org/10.1056/NEJMoa2511774)
3. BioSpace. *Pfizer ends oral GLP-1 candidate danuglipron due to liver injury.* Published April 2025. Accessed October 2025.[https://www.drugs.com/news/pfizer-ends-testing-obesity-pill-danuglipron-after-possible-liver-injury-124534.html](https://www.drugs.com/news/pfizer-ends-testing-obesity-pill-danuglipron-after-possible-liver-injury-124534.html)
4. Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. *Obesity Pillars*, *12*, 100127. [https://doi.org/10.1016/j.obpill.2024.100127](https://doi.org/10.1016/j.obpill.2024.100127)
5. Gonzalez-Rellan, M. J., & Drucker, D. J. (2025). The expanding benefits of GLP-1 medicines. *Cell Reports. Medicine*, *6*(7), 102214. [https://doi.org/10.1016/j.xcrm.2025.102214](https://doi.org/10.1016/j.xcrm.2025.102214)
6. Gleason, P. P., Urick, B. Y., Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. *Journal of Managed Care & Specialty Pharmacy*, *30*(8), 860–867. [https://doi.org/10.18553/jmcp.2024.23332](https://doi.org/10.18553/jmcp.2024.23332)
7. *Spending on GLP-1s has grown dramatically. Here are the details.* (2025, August 27). American Medical Association. [https://www.ama-assn.org/public-health/prevention-wellness/spending-glp-1s-has-grown-dramatically-here-are-details](https://www.ama-assn.org/public-health/prevention-wellness/spending-glp-1s-has-grown-dramatically-here-are-details)
8. AMA passes resolution calling for expanded access to anti-obesity medications. (n.d.). Retrieved October 8, 2025, from [https://www.endocrine.org/news-and-advocacy/news-room/2025/ama-passes-resolution-calling-for-expanded-access-to-anti-obesity-medications](https://www.endocrine.org/news-and-advocacy/news-room/2025/ama-passes-resolution-calling-for-expanded-access-to-anti-obesity-medications)
[](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKtUkenECFXKyInwMIkDixZEKW7kQSK1vpx6%2FFCm3JlSX3cyJOQSdxRGQIjIlxYJ7PqmQb81%2Bi4u%2FrfEgygAwtgWk0LbEl5v4oK%2F7Yhro3Lxuf2W1ruQ1X0Fc8glIMBvVoFsKkdXhmRWEY5opSqiHE%2FWKaxhaVfGmFMTOLW4fLg7eZU9yQ%3D&webInteractiveContentId=209041299597&portalId=5412465)
###### Category
- [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices)
- [Trends & Insights](https://blog.healthverity.com/tag/trends-insights)
- [HEOR](https://blog.healthverity.com/tag/heor)
- [Marketplace](https://blog.healthverity.com/tag/marketplace)
- [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership)
- [taXonomy](https://blog.healthverity.com/tag/taxonomy)
- [Industry Updates](https://blog.healthverity.com/tag/industry-updates)
- [Case Studies](https://blog.healthverity.com/tag/case-studies)
- [Government](https://blog.healthverity.com/tag/government)
- [Commercial Pharmaceutical](https://blog.healthverity.com/tag/commercial-pharmaceutical)
- [AI](https://blog.healthverity.com/tag/ai)
- [eXOs](https://blog.healthverity.com/tag/exos)
- [Audiences](https://blog.healthverity.com/tag/audiences)
- [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways)
- [Notes](https://blog.healthverity.com/tag/notes)
- [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases)
###### Popular Post
- [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals)
- [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies)
- [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims)
- [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)
- [What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage)
###### Subscribe
### Similar Blogs
[](https://blog.healthverity.com/tallying-the-troops-tracking-cost-implications-under-ira-part-d-reforms)
#### [TrOOPs: Tracking cost implications under IRA Part D reforms](https://blog.healthverity.com/tallying-the-troops-tracking-cost-implications-under-ira-part-d-reforms)
By [Clayton Hale, MS](https://blog.healthverity.com/author/clayton-hale-ms) 10 July 2026
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
[READ MORE](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)
[](https://blog.healthverity.com/electronic-medical-records)
#### [A guide to optimizing real-world data: Electronic medical records](https://blog.healthverity.com/electronic-medical-records)
By [HealthVerity](https://blog.healthverity.com/author/healthverity) 13 August 2024
The healthcare industry has moved away from paper charts and file folders in favor of electronic...
[READ MORE](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)
[.png?width=352&name=building-guardrails-for-ai-featured%20(1).png)](https://blog.healthverity.com/building-guardrails-for-ai-driven-real-world-data-programs)
#### [Building guardrails for AI-driven real-world data programs](https://blog.healthverity.com/building-guardrails-for-ai-driven-real-world-data-programs)
By [HealthVerity](https://blog.healthverity.com/author/healthverity) 12 February 2026
AI is rapidly reshaping how real-world data (RWD) is generated and analyzed across healthcare...
[READ MORE](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care)
#### Who we serve
- [Life Sciences](https://healthverity.com/life-sciences/)
- [Government](https://healthverity.com/government/)
- [Insurance](https://healthverity.com/insurance/)
- [Channel Partners](https://healthverity.com/channel-partners/)
- [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/)
#### How we help
- [HealthVerity Marketplace](https://healthverity.com/marketplace/)
- [HealthVerity Mastersets](https://healthverity.com/mastersets/)
- [HealthVerity FLOW](https://healthverity.com/flow/)
- [The IPGE Approach](https://healthverity.com/ipge-approach/)
#### Resources
- [HealthVerity Blog](https://blog.healthverity.com/)
- [News & Events](https://healthverity.com/resources/news-and-events/)
- [Resource Library](https://healthverity.com/resources/resource-library/)
- [Publications](https://healthverity.com/resources/publications/)
#### Our company
- [About Us](https://healthverity.com/about-us/)
- [Leadership](https://healthverity.com/about-us/#leadership)
- [Board of Directors](https://healthverity.com/about-us/#board)
- [Careers](https://healthverity.com/careers/)
- [Contact](https://healthverity.com/contact/)
©2026 HealthVerity, Inc. | [Terms & Conditions](https://healthverity.com/terms-and-conditions/) | [Privacy Policy](https://healthverity.com/privacy-policy/)
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Organization",
"name" : "HealthVerity"
},
"datePublished" : "2025-10-09",
"description" : "Discover how GLP-1 receptor agonists like semaglutide and tirzepatide are transforming obesity treatment. Learn why integrating medical claims with real-world clinical data is essential to track adherence, track outcomes, and monitor metabolic disease.",
"headline" : "GLP-1 real-world data for obesity: A new standard for metabolic care",
"keywords" : [ "GLP-1 real-world data", "obesity treatment trends", "semaglutide", "tirzepatide", "metabolic care", "GLP-1 adherence rates", "healthcare spending on GLP-1", "HEOR analytics", "RWE for obesity", "clinical data integration" ],
"mainEntityOfPage" : {
"@id" : "https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://healthverity.com/wp-content/uploads/2023/08/healthverity-logo.png"
},
"name" : "HealthVerity"
}
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "FAQPage",
"mainEntity" : [ {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "In clinical trials, GLP-1 receptor agonists such as semaglutide and tirzepatide have demonstrated a 15% to 25% reduction in body weight. This level of efficacy is actively transforming metabolic disease treatment, approaching the results traditionally only seen with bariatric surgery."
},
"name" : "How effective are GLP-1 drugs for weight loss compared to bariatric surgery?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Demand for these treatments has skyrocketed. U.S. spending on GLP-1 medications surged over 500% between 2018 and 2023, climbing from $13.7 billion to $71.7 billion."
},
"name" : "How much has U.S. spending on GLP-1 medications increased?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Yes, there is a massive gap. In clinical trials, over 85% of patients stayed on GLP-1 therapy. However, real-world data reveals that only 32% of obese patients remained on a GLP-1 therapy after one year, with just 27% meeting standard adherence thresholds."
},
"name" : "Is there a difference in GLP-1 adherence between clinical trials and the real world?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "Medical claims alone lack clinical context. By linking claims to clinical data like BMI, A1c, and liver markers (ALT/AST), Health Economics and Outcomes Research (HEOR) and epidemiology teams can accurately model the true impact of weight loss, monitor adverse events, and understand the full obesity patient journey."
},
"name" : "Why is it important to link medical claims with clinical data for obesity research?"
}, {
"@type" : "Question",
"acceptedAnswer" : {
"@type" : "Answer",
"text" : "HealthVerity anchors its solution with closed medical and pharmacy claims covering over 300 million patients (9+ years of history). It then integrates this with lab data from the nation's two largest outpatient labs and EHR notes, allowing teams to analyze the full obesity patient journey in one place without stitching together fragmented data sources."
},
"name" : "How does HealthVerity help pharmaceutical companies analyze GLP-1 data?"
} ]
}
```
```json
{
"@context" : "https://schema.org",
"@type" : "BreadcrumbList",
"itemListElement" : [ {
"@type" : "ListItem",
"item" : "https://healthverity.com/",
"name" : "Home",
"position" : 1
}, {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/",
"name" : "Blog",
"position" : 2
}, {
"@type" : "ListItem",
"item" : "https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care",
"name" : "GLP-1 real-world data for obesity: A new standard for metabolic care",
"position" : 3
} ]
}
```